In general, biotechnology companies, and Neovacs in particular, are increasingly promoting their preclinical research projects by collaboration. Indeed, in recent years, scientific data has become very complex. For each project, the need is to find the best skills at an international level. In addition to the technological context, the economic context pushes the drug industry to these collaborations. It is important for laboratories to optimize the ratio between benefits and risks. Pharmaceutical industry and academics find many interests in these partnerships, as collaborative innovation promotes multidisciplinarity, which is vector of ingenuity.
Since its inception, Neovacs has formed close links with numerous laboratories and research institutes worldwide. To date, Neovacs participates in a program co-funded by the ANR (National Agency for Research) : the AllergyVac project. Several collaborations with public laboratories are underway in France and worldwide.
ANR : projet allergyvacs : https://anr.fr/Projet-ANR-18-CE18-0023
University North Carolina